Literature DB >> 16404596

PET imaging of brain astrocytoma with 1-11C-acetate.

Ren-Shyan Liu1, Cheng-Pei Chang, Lee-Shing Chu, Yum-Kung Chu, Hung-Jen Hsieh, Chi-Wei Chang, Bang-Hung Yang, Shan-Hui Yen, Min-Chao Huang, Su-Quin Liao, Shin-Hwa Yeh.   

Abstract

PURPOSE: The purpose of this study was to assess the use of 1-(11)C-acetate (ACE) as a metabolic tracer for the detection and characterisation of astrocytomas.
METHODS: Positron emission tomography (PET) studies with ACE and 2-(18)F-fluoro-2-deoxy-D-glucose (FDG) were performed sequentially in 26 patients with primary astrocytomas. Images were analysed by visual interpretation and determination of the tumour to cortex ratio (T/C ratio) and standardised uptake value (SUV). The tumour uptake was visually scored into three grades as compared with the contralateral cortex: clearly lower (-), almost equal (+) and clearly higher (++).
RESULTS: There were 85% of astrocytomas with ++ ACE uptake, 15% with + ACE uptake and none with - ACE uptake. Only 19% of astrocytomas had ++ FDG uptake. Thirty-seven percent of high-grade astrocytomas had + FDG uptake and 37% had - FDG uptake. The sensitivity and specificity of the FDG T/C ratio in discriminating high-grade from low-grade astrocytomas were 79% and 100%, respectively, at the cutoff value of 0.75. Using 2.33 as the cutoff value of the ACE T/C ratio, the sensitivity and specificity were 42% and 86%, respectively. FDG was better than ACE in discriminating high-grade from low-grade astrocytomas. T/C ratios and SUVs of FDG uptake of tumours correlated with the histological grades, but those of ACE uptake did not.
CONCLUSION: ACE appears to be a promising tracer for use in the detection of primary astrocytomas, but is of limited value in the differentiation of high- and low-grade astrocytomas. ACE is complementary to FDG for the diagnosis and characterisation of astrocytoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16404596     DOI: 10.1007/s00259-005-0023-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  27 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Metabolism of [14C]leucine and [14C]acetate in sensorimotor cortex, thalamus, caudate nucleus and cerebellum of the cat.

Authors:  S Berl; T L Frigyesi
Journal:  J Neurochem       Date:  1968-09       Impact factor: 5.372

3.  Cancer or inflammation? A Holy Grail for nuclear medicine.

Authors:  S M Larson
Journal:  J Nucl Med       Date:  1994-10       Impact factor: 10.057

4.  Can the standardized uptake value characterize primary brain tumors on FDG-PET?

Authors:  R Hustinx; R J Smith; F Benard; A Bhatnagar; A Alavi
Journal:  Eur J Nucl Med       Date:  1999-11

Review 5.  Clinical application of PET for the evaluation of brain tumors.

Authors:  R E Coleman; J M Hoffman; M W Hanson; H D Sostman; S C Schold
Journal:  J Nucl Med       Date:  1991-04       Impact factor: 10.057

6.  Preferential labeling of glial and meningial brain tumors with [2-(14)C]acetate.

Authors:  G A Dienel; D Popp; P D Drew; K Ball; A Krisht; N F Cruz
Journal:  J Nucl Med       Date:  2001-08       Impact factor: 10.057

7.  FDG-PET in the selection of brain lesions for biopsy.

Authors:  M W Hanson; M J Glantz; J M Hoffman; A H Friedman; P C Burger; S C Schold; R E Coleman
Journal:  J Comput Assist Tomogr       Date:  1991 Sep-Oct       Impact factor: 1.826

8.  Preferential utilization of acetate by astrocytes is attributable to transport.

Authors:  R A Waniewski; D L Martin
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

9.  Carbon-11-acetate PET imaging in renal disease.

Authors:  P Shreve; P C Chiao; H D Humes; M Schwaiger; M D Gross
Journal:  J Nucl Med       Date:  1995-09       Impact factor: 10.057

10.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution.

Authors:  K Hamacher; H H Coenen; G Stöcklin
Journal:  J Nucl Med       Date:  1986-02       Impact factor: 10.057

View more
  15 in total

1.  The roles of 11C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma.

Authors:  Soyoung Kim; Dongwoo Kim; Se Hoon Kim; Mi-Ae Park; Jong Hee Chang; Mijin Yun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-06       Impact factor: 9.236

2.  Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma.

Authors:  Yoshiro Kawase; Yuka Yamamoto; Reiko Kameyama; Nobuyuki Kawai; Nobuyuki Kudomi; Yoshihiro Nishiyama
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

Review 3.  Non-FDG PET/CT in Diagnostic Oncology: a pictorial review.

Authors:  Francesco Giammarile; Paolo Castellucci; Rudi Dierckx; Enrique Estrada Lobato; Mohsen Farsad; Roland Hustinx; Amirreza Jalilian; Olivier Pellet; Susana Rossi; Diana Paez
Journal:  Eur J Hybrid Imaging       Date:  2019-11-29

4.  1-[11C]-acetate PET imaging in head and neck cancer--a comparison with 18F-FDG-PET: implications for staging and radiotherapy planning.

Authors:  Aijun Sun; Jens Sörensen; Mikael Karlsson; Ingela Turesson; Bengt Langström; Per Nilsson; Lena Cederblad; Jan Bertling; Katrine Riklund; Silvia Johansson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-05       Impact factor: 9.236

Review 5.  Application of metabolic PET imaging in radiation oncology.

Authors:  Aizhi Zhu; David M Marcus; Hui-Kuo G Shu; Hyunsuk Shim
Journal:  Radiat Res       Date:  2012-02-17       Impact factor: 2.841

6.  11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET.

Authors:  Y Yamamoto; Y Nishiyama; N Kimura; R Kameyama; N Kawai; T Hatakeyama; M Kaji; M Ohkawa
Journal:  Mol Imaging Biol       Date:  2008-06-10       Impact factor: 3.488

Review 7.  Interaction of brain fatty acid-binding protein with the polyunsaturated fatty acid environment as a potential determinant of poor prognosis in malignant glioma.

Authors:  Marwa E Elsherbiny; Marwan Emara; Roseline Godbout
Journal:  Prog Lipid Res       Date:  2013-08-24       Impact factor: 16.195

8.  The clinical use of PET with (11)C-acetate.

Authors:  Ilaria Grassi; Cristina Nanni; Vincenzo Allegri; Joshua James Morigi; Gian Carlo Montini; Paolo Castellucci; Stefano Fanti
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

9.  Choroid Plexus as the Best Reference Region for Standardized Uptake Value Analysis on C11-Acetate PET/CT for Grading and Predicting Prognosis in Patients with Cerebral Gliomas.

Authors:  Dongwoo Kim; Arthur Cho; Sang Hyun Hwang; KwanHyeong Jo; Jong Hee Chang; Mijin Yun
Journal:  Nucl Med Mol Imaging       Date:  2020-11-16

10.  The role of astrocytes in CNS tumors: pre-clinical models and novel imaging approaches.

Authors:  Emma R O'Brien; Clare Howarth; Nicola R Sibson
Journal:  Front Cell Neurosci       Date:  2013-04-16       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.